CA2672220A1 - Impaired wound healing compositions and treatments - Google Patents

Impaired wound healing compositions and treatments Download PDF

Info

Publication number
CA2672220A1
CA2672220A1 CA002672220A CA2672220A CA2672220A1 CA 2672220 A1 CA2672220 A1 CA 2672220A1 CA 002672220 A CA002672220 A CA 002672220A CA 2672220 A CA2672220 A CA 2672220A CA 2672220 A1 CA2672220 A1 CA 2672220A1
Authority
CA
Canada
Prior art keywords
connexin
wound
polynucleotide
healing
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002672220A
Other languages
English (en)
French (fr)
Inventor
David L. Becker
Colin R. Green
Bradford J. Duft
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inflammx Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2672220A1 publication Critical patent/CA2672220A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002672220A 2006-12-11 2007-12-11 Impaired wound healing compositions and treatments Abandoned CA2672220A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87440406P 2006-12-11 2006-12-11
US60/874,404 2006-12-11
PCT/US2007/025446 WO2008073479A2 (en) 2006-12-11 2007-12-11 Anticonnexin polynucleotides as impaired wound healing compositions

Publications (1)

Publication Number Publication Date
CA2672220A1 true CA2672220A1 (en) 2008-06-19

Family

ID=39386432

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002672220A Abandoned CA2672220A1 (en) 2006-12-11 2007-12-11 Impaired wound healing compositions and treatments

Country Status (15)

Country Link
US (5) US8063023B2 (enExample)
EP (3) EP2543377A1 (enExample)
JP (3) JP5431949B2 (enExample)
KR (1) KR101521306B1 (enExample)
CN (2) CN103520197B (enExample)
AU (1) AU2007333535B2 (enExample)
BR (1) BRPI0721094A2 (enExample)
CA (1) CA2672220A1 (enExample)
DK (1) DK2101791T3 (enExample)
ES (1) ES2527131T3 (enExample)
PL (1) PL2101791T3 (enExample)
PT (1) PT2101791E (enExample)
RU (1) RU2521329C2 (enExample)
SI (1) SI2101791T1 (enExample)
WO (1) WO2008073479A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2662088A3 (en) 2005-02-03 2014-02-19 Coda Therapeutics Limited Anti-connexin compounds and uses thereof
JP5960944B2 (ja) 2006-11-15 2016-08-02 コーダ セラピューティクス， インコーポレイテッド 創傷治癒のための改善された方法および組成物
ES2527131T3 (es) 2006-12-11 2015-01-20 Coda Therapeutics, Inc. Polinucleótidos anticonexina como composiciones para la curación alterada de heridas
US20080249044A1 (en) * 2007-04-03 2008-10-09 Masaya Tanaka Nucleic acid external skin formulation
AU2008335718A1 (en) * 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
CA2709151A1 (en) * 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
US8975237B2 (en) 2007-12-21 2015-03-10 Coda Therapeutics, Inc. Treatment of fibrotic conditions
EP2237795A2 (en) * 2007-12-21 2010-10-13 Coda Therapeutics, Inc. Use of anti-connexin polypeptide agent in combination with anti-connexin polynucleotide agent for the treatment of fibrotic conditions
WO2012076985A2 (en) * 2010-12-06 2012-06-14 The University Of British Columbia Granzyme b inhibitor compositions, methods and uses for promoting wound healing
GB201117538D0 (en) * 2011-10-11 2011-11-23 Royal Veterinary College The Methods
CN104271142B (zh) 2012-03-01 2017-07-04 福斯特斯特林研究公司 含有α连接蛋白C‑末端(ACT)肽的局部凝胶
CN104736709A (zh) * 2012-03-27 2015-06-24 科达治疗公司 基于钙粘蛋白调节的组合物和治疗
US9156896B2 (en) 2013-03-15 2015-10-13 Coda Therapeutics, Inc. Wound healing compositions and treatments
WO2015139047A2 (en) * 2014-03-14 2015-09-17 Coda Therapeutics Treatment of resistant lesions
JP6683686B2 (ja) 2014-08-22 2020-04-22 オークランド ユニサービシーズ リミティド チャネル調節剤
CN108367017A (zh) * 2015-08-13 2018-08-03 索马根尼科斯公司 用于伤口愈合的短小发夹rna与微rna的组合物以及方法
US11096832B2 (en) * 2016-09-27 2021-08-24 Smith & Nephew Plc Wound closure devices with dissolvable portions
WO2018199777A1 (en) 2017-04-28 2018-11-01 Auckland Uniservices Limited Methods of treatment and novel constructs
CN108588075A (zh) * 2018-05-03 2018-09-28 天德悦（北京）生物科技有限责任公司 人Cx43基因干扰序列、shRNA-Cx43病毒及低表达Cx43蛋白的细胞系
EP4232157A4 (en) 2020-10-22 2024-08-28 Xequel Bio, Inc. PEPTIDE FORMULATIONS AND ASSOCIATED OPHTHALMIC USES
RU2754383C1 (ru) * 2020-12-07 2021-09-01 Федеральное Государственное Бюджетное Учреждение "Национальный Медицинский Исследовательский Центр Эндокринологии" Министерства Здравоохранения Российской Федерации (Фгбу "Нмиц Эндокринологии" Минздрава России) Способ лечения неинфицированного послеоперационного раневого дефекта стопы при отсутствии признаков критической ишемии конечности у больных с нейропатической и нейроишемической формой синдрома диабетической стопы

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0539594Y2 (enExample) * 1988-08-05 1993-10-07
US5004810A (en) 1988-09-30 1991-04-02 Schering Corporation Antiviral oligomers
US5166195A (en) 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
GB9425930D0 (en) 1994-12-22 1995-02-22 Procter & Gamble Silicone compositions
WO1998024797A1 (en) 1996-12-02 1998-06-11 Dyad Pharmaceutical Corporation Antisense inhibition of human adhesion molecules
RU2147240C1 (ru) * 1998-02-16 2000-04-10 Рязанский областной клинический кожно-венерологический диспансер Препарат для лечения длительно незаживающих инфицированных язв и ран
CA2361251C (en) * 1999-01-27 2011-03-08 David L. Becker Formulations comprising antisense nucleotides to connexins
US7250397B2 (en) 2000-02-23 2007-07-31 Zealand Pharma A/S Antiarrhythmic peptides
US20050119211A1 (en) * 2001-05-18 2005-06-02 Sirna Therapeutics, Inc. RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA)
JP2005509621A (ja) 2001-10-17 2005-04-14 ユニバーシティ オブ ウェールズ カレッジ オブ メディスン ギャップ結合ならびにｅｄｈｆ
CN1939529A (zh) * 2002-01-29 2007-04-04 Wyeth公司 用于调节连接蛋白半通道的组合物和方法
JP5838017B2 (ja) 2003-12-03 2015-12-24 コーダ セラピューティクス， インコーポレイテッド コネキシンに対して標的化されたアンチセンス化合物およびその使用方法
DE102004027422A1 (de) 2004-06-04 2005-12-29 Boehringer Ingelheim Microparts Gmbh Vorrichtung zur Aufnahme von Blut und Abtrennung von Blutbestandteilen
HUE038099T2 (hu) 2004-12-21 2018-09-28 Musc Found For Res Dev Kompozíciók és módszerek sebgyógyulás és szöveti regeneráció elõsegítésére
EP2662088A3 (en) 2005-02-03 2014-02-19 Coda Therapeutics Limited Anti-connexin compounds and uses thereof
JP5960944B2 (ja) 2006-11-15 2016-08-02 コーダ セラピューティクス， インコーポレイテッド 創傷治癒のための改善された方法および組成物
ES2527131T3 (es) 2006-12-11 2015-01-20 Coda Therapeutics, Inc. Polinucleótidos anticonexina como composiciones para la curación alterada de heridas
CN101765423B (zh) 2007-05-31 2014-08-06 安特里奥公司 核酸纳米粒子和其用途
CA2709151A1 (en) 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
AU2008335718A1 (en) 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments

Also Published As

Publication number Publication date
EP2543377A1 (en) 2013-01-09
CN101835476B (zh) 2016-08-17
RU2521329C2 (ru) 2014-06-27
US20080242631A1 (en) 2008-10-02
JP2013173796A (ja) 2013-09-05
US20170240905A1 (en) 2017-08-24
CN103520197B (zh) 2017-11-21
EP2543378A1 (en) 2013-01-09
JP5911454B2 (ja) 2016-04-27
SI2101791T1 (sl) 2015-02-27
KR20090118910A (ko) 2009-11-18
ES2527131T3 (es) 2015-01-20
EP2101791B1 (en) 2014-09-10
KR101521306B1 (ko) 2015-05-18
HK1136213A1 (en) 2010-06-25
AU2007333535A1 (en) 2008-06-19
AU2007333535B2 (en) 2014-04-17
CN103520197A (zh) 2014-01-22
US9029339B2 (en) 2015-05-12
PL2101791T3 (pl) 2015-04-30
BRPI0721094A2 (pt) 2014-02-11
US20130143952A1 (en) 2013-06-06
RU2009126594A (ru) 2011-01-20
US9637745B2 (en) 2017-05-02
US8685940B2 (en) 2014-04-01
WO2008073479A2 (en) 2008-06-19
DK2101791T3 (en) 2015-01-05
PT2101791E (pt) 2014-12-18
CN101835476A (zh) 2010-09-15
US8063023B2 (en) 2011-11-22
JP5431949B2 (ja) 2014-03-05
US20120289579A1 (en) 2012-11-15
EP2101791A2 (en) 2009-09-23
US20150315598A1 (en) 2015-11-05
WO2008073479A3 (en) 2008-08-07
JP2015063565A (ja) 2015-04-09
JP2010512404A (ja) 2010-04-22

Similar Documents

Publication Publication Date Title
US9637745B2 (en) Impaired wound healing compositions and treatments
US20100279921A1 (en) Impaired wound healing compositions and treatments
US20110038920A1 (en) Wound healing compositions and treatments
CA2669832A1 (en) Improved methods and compositions for wound healing
AU2008343755A1 (en) Use of anti-connexin polynucleotides and peptides for the treatment ofabnormal or excessive scars
EP2237795A2 (en) Use of anti-connexin polypeptide agent in combination with anti-connexin polynucleotide agent for the treatment of fibrotic conditions
US20180028468A1 (en) Sustained release drug delivery devices
AU2014204482B2 (en) Anticonnexin polynucleotides as impaired wound healing compositions
HK1136213B (en) Anticonnexin polynucleotides as impaired wound healing compositions

Legal Events

Date Code Title Description
EEER Examination request
EEER Examination request

Effective date: 20121211

FZDE Discontinued

Effective date: 20190405